US2021283195A1PendingUtilityA1

Media supplements and methods to culture human gastrointestinal anaerobic microorganisms

Assignee: NUBIYOTA LLCPriority: Sep 14, 2011Filed: May 26, 2021Published: Sep 16, 2021
Est. expirySep 14, 2031(~5.2 yrs left)· nominal 20-yr term from priority
C12N 1/20Y02A50/30C12R 2001/01A61K 35/747C12R 2001/145C12N 1/205A61K 35/74A61P 1/12A61K 35/745A61P 31/04A61P 29/00
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A media supplement for culturing anaerobic bacteria is provided which comprises a filtrate of eilluent from a chemostat vessel in which a target bacterial ecosystem has been culnn-ed. Methods of using the supplement for culturing or isolating anaerobic microbial strains or cormmmities, particularly anaerobic bacteria from the human gut, are also provided.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method of isolating anaerobic bacteria from human gut, comprising:
 (a) culturing a fecal sample comprising a microbial community of the human gut in culture media in a single-stage chemostat under conditions replicating normal human colonic gastrointestinal tract, until equilibrium is reached;   (b) diluting the culture and plating onto anaerobe agar supplemented with a media supplement, and optionally supplemented with defibrinated sheep blood, wherein the media supplement comprises a filtrate of effluent from a chemostat vessel in which a target bacterial ecosystem has been cultured,   wherein the target bacterial ecosystem has been cultured in media comprising: 0.2% w/v Peptone; 0.2% w/v Yeast extract; 0.2% w/v NaHCO 3 ; 0.2% w/v Pectin; 0.2% w/v Arabinogalactan; 0.3% w/v Casein; 0.5% w/v unmodified wheat starch; 0.1% w/v inulin; 0.05% w/v bile salts; 0.05% w/v L cysteine HCl; 0.0001% w/v CaC1 2 ; 0.0001% w/v NaCl; 0.0004% w/v K 2 HPO 4 ; 0.0004% w/v KH 2 PO 4 ; 0.0001% w/v MgSO 4 ; 0.00005% w/v Hemin; and 0.00001% w/v menadione; and   wherein the target bacterial ecosystem comprises  Bacteroides ovatus, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium longum, Collinsella aerofaciens, Eubacterium rectale, Faecalibacterium prausnitzii, Parabacteroides distasonis, Roseburia inulinivorans , and  Ruminococcus obeum;      (c) incubating plates in an anaerobe chamber;   (d) purifying individual anaerobic bacterial colonies grown in step (c) to isolate anaerobic bacteria from the human gut; and   optionally, culturing the purified individual anaerobic bacterial colonies from step (d) in liquid culture in a single-stage chemostat under conditions replicating normal human colonic gastrointestinal tract, optionally wherein the media supplement of claim  57  is used to supplement culture media at about 1% v/v to about 10% v/v;   such that isolates of anaerobic bacteria are obtained.   
     
     
         2 . The method of  claim 1 , wherein the anaerobe chamber contains an atmosphere of N 2 , CO 2  or H 2 , or a mixture thereof. 
     
     
         3 . The method of  claim 1 , wherein the target bacterial ecosystem comprises a human fecal sample. 
     
     
         4 . The method of  claim 3 , wherein the human fecal sample is a 10% w/v fecal slurry supernatant or a 20% w/v fecal slurry supernatant. 
     
     
         5 . The method of  claim 1 , wherein the culture media of step a) further comprises 0.2% w/v Xylan. 
     
     
         6 . The method of  claim 1 , wherein the anaerobic bacteria obtained is  Faecalibacterium prausnitzii  or  Ruminococcus callidus  (ATCC27760). 
     
     
         7 . The method of  claim 1 , wherein obtaining at least one of the anaerobic bacteria of  Faecalibacterium prausnitzii, Ruminococcus callidus  (ATCC27760), or a  Roseburia  species serves as a positive indicator of effectiveness of the method. 
     
     
         8 . The method of  claim 1 , wherein the fecal sample and the target bacterial ecosystem are isolated from the same human fecal sample.

Join the waitlist — get patent alerts

Track US2021283195A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.